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152Objective: The study objective was to identify factors associated with death and cardiac transplantation in in-
fants undergoing the Norwood procedure and to determine differences in associations that might favor the mod-
ified Blalock–Taussig shunt or a right ventricle-to-pulmonary artery shunt.
Methods:We used competing risks methodology to analyze death without transplantation, cardiac transplanta-
tion, and survival without transplantation. Parametric time-to-event modeling and bootstrapping were used to
identify independent predictors.
Results:Data from 549 subjects (follow-up, 2.7 0.9 years) were analyzed. Mortality risk was characterized by
early and constant phases; transplant was characterized by only a constant phase. Early phase factors associated
with death included lower socioeconomic status (P ¼ .01), obstructed pulmonary venous return (P< .001),
smaller ascending aorta (P¼ .02), and anatomic subtype. Constant phase factors associated with death included
genetic syndrome (P<.001) and lower gestational age (P<.001). The right ventricle-to-pulmonary artery shunt
demonstrated better survival in the 51% of subjects who were full term with aortic atresia (P<.001). The mod-
ified Blalock–Taussig shunt was better among the 4% of subjects who were preterm with a patent aortic valve
(P ¼ .003). Lower pre-Norwood right ventricular fractional area change, pre-Norwood surgery, and anatomy
other than hypoplastic left heart syndrome were independently associated with transplantation (all P<.03),
but shunt type was not (P ¼ .43).
Conclusions: Independent risk factors for intermediate-term mortality include lower socioeconomic status,
anatomy, genetic syndrome, and lower gestational age. Term infants with aortic atresia benefited from a right
ventricle-to-pulmonary artery shunt, and preterm infants with a patent aortic valve benefited from a modified
Blalock–Taussig shunt. Right ventricular function and anatomy, but not shunt type, were associated with trans-
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The risk of mortality after the Norwood procedure for hypo-
plastic left heart syndrome (HLHS) and other single right
ventricle anomalies with arch obstruction remains signifi-
cant. Risk factors for death and transplantation after the
Norwood procedure may be thought of as occurring in 2 cat-
egories: factors intrinsic to the patient that are traditionally
considered nonmodifiable, such as anatomic subtype,
weight, gestational age, and pulmonary venous obstruction,
and modifiable factors that may be subject to practice vari-
ation, such as perioperative management, timing of surgery,
technique, and perfusion strategies. The Pediatric Heart
Network Single Ventricle Reconstruction (PHN SVR) trial
prospectively collected preoperative, operative, and postop-
erative multi-institutional data from more than 500ery c July 2012
Abbreviations and Acronyms
AA ¼ aortic atresia
AS ¼ aortic stenosis
HLHS ¼ hypoplastic left heart syndrome
HR ¼ hazard ratio
MA ¼ mitral atresia
MBTS ¼ modified Blalock–Taussig shunt
MS ¼ mitral stenosis
OPVR ¼ obstructed pulmonary venous return
PHN
SVR
¼ Pediatric Heart Network Single
Ventricle Reconstruction
RVPAS ¼ right ventricle-to-pulmonary artery
shunt
SES ¼ socioeconomic status
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Dnewborns with HLHS and related single right ventricle
anomalies. This trial demonstrated that a Norwood proce-
dure with a right ventricle-to-pulmonary artery shunt
(RVPAS), compared with a modified Blalock–Taussig shunt
(MBTS), was associated with better transplant-free survival
12 months after randomization.1 By using all available
follow-up (2.7  0.9 years in event-free subjects), we ana-
lyzed the PHN SVR dataset to achieve the following goals:
to estimate the cumulative incidence of death and cardiac
transplantation in subjects who have undergone the
Norwood procedure, to determine the association of tradi-
tionally nonmodifiable factors with outcomes using para-
metric regression modeling, and to determine the
interaction of shunt type with these factors. We also sought
to use this information to develop an algorithm to tailor
shunt type to the patient profile.MATERIALS AND METHODS
Study Design
TheSVRtrial has been described in detail in earlier reports.1,2 Enrollment
occurred betweenMay 2005 and July 2008 at 15 centers in the United States
and Canada. Briefly, subjects with single right ventricle anomalies with
systemic outflow obstruction were randomly assigned to receive an MBTS
or RVPAS during the Norwood procedure. Randomization was stratified
by the presence versus absence of aortic atresia (AA) and obstructed
pulmonary venous return (OPVR), with dynamic balancing within
surgeon. The primary trial end point was death or cardiac transplantation
at 1 year post-randomization. In addition, an end-of-trial contact was com-
pleted in summer 2009 to obtain maximal follow-up on all subjects. A key
secondary end point was time to death or cardiac transplantation at the
time of last follow-up and is the focus of this report.
The trial protocol was approved by the institutional review board or
ethics committee of all institutions, and a parent or legal guardian of
each subject provided written informed consent.
Patient Sample
There were 555 neonates randomized in the trial. The analysis cohort
included 549 subjects. We excluded 5 subjects who did not undergoThe Journal of Thoracic and Caa Norwood procedure and 1 subject who withdrew from the trial in the first
week after randomization, and for whom no additional data were collected.
Data Collection
This report is based on an analysis of early and nonmodifiable patient
factors. Detailed information on birth characteristics, patient demograph-
ics, and pre-Norwood procedure medical history was collected on stan-
dardized forms. Socioeconomic status (SES) was assigned using a US
census–based score derived from 6 measures related to income, housing,
and occupational-related features of the subject’s census block tract3 at
the time of randomization. Cause of death was assigned by a 5-member
panel who arrived at consensus decision on each event after independent
review by eachmember.4 The panel consisted of the SVRStudy Chair, a pe-
diatric cardiologist, a pediatric cardiac intensivist, and 2 pediatric cardiac
surgeons.
Two-dimensional and Doppler echocardiographic data from a standard-
ized echocardiogram obtained before the Norwood procedure were used in
this analysis. All echocardiograms were interpreted centrally at a core lab-
oratory (Medical College of Wisconsin). Variables used in this report in-
clude right ventricular fractional area change, presence versus absence of
antegrade flow in the aorta (patent vs atretic aortic valve), and no/mild ver-
sus moderate/severe valve regurgitation (aortic, mitral, tricuspid).
Definitions
The type of shunt used in the Norwood procedure (MBTS or RVPAS)
was defined as the shunt in place at the end of the Norwood procedure,
which differed from the randomly assigned shunt for 48 subjects (9%). Pre-
term was defined as gestational age less than 37 weeks. OPVR was defined
as the use of postnatal intervention directed at the atrial septum, including
balloon septostomy, open atrial septectomy, and urgent Norwood
procedure.2
Statistical Methods
The primary end point of the SVR trial was a composite of the earliest
occurrence of death or transplant. However, we hypothesized that the haz-
ard functions for death and transplant might differ, as well as the factors
associated with those end points. Therefore, outcomes at the time of last
follow-up were examined using a competing risks framework. In addition,
we hypothesized that the factors associated with these outcomes might dif-
fer according to time domain. Parametric regression modeling methodol-
ogy allowed us to fit early, constant, and late phase hazard functions and
to test their significance.
Summary statistics are reported asmean standard deviation or median
and interquartile range. Mean or median imputation was used; 2% or less
data were missing in variables on which imputation was performed, with
the exception of highest lactate (18%) and fractional area change (8%).
Genetic syndrome and nonsyndromic abnormalities were analyzed with
an explicit category for unknown status. All outcomes were measured as
time since randomization. The following independent and mutually exclu-
sive states were defined for analysis: death, cardiac transplantation, and
transplant-free survival (ie, no transition to another state). Nonparametric
Kaplan–Meier estimates of freedom from death and transplantation were
obtained and used to inform starting values for parametric model estima-
tion of the hazard functions for each state and the number of phases. Com-
peting risks cumulative incidence event rate estimation was used.
Univariate (Table E1) and multivariable modeling were conducted using
the parametric regression model.5 Bootstrap resampling was used to esti-
mate the reliability of each factor selected by stepwise regression for the
multivariable model.6,7 We retained main effects in the model if the term
had reliability of 50% or more and a P value less than .05. In addition to
the identification of independent associated factors, the interaction of
shunt type with each candidate factor was examined unless there were
insufficient events to achieve model convergence. The final multivariablerdiovascular Surgery c Volume 144, Number 1 153
FIGURE 1. Proportion of subjects in each of 3 competing mutually exclu-
sive end states: death, transplant, and alive without transplant for all 549
subjects (solid curves). Dashed curves represent the pointwise 68% (1
standard error) confidence bands based on the parametric fit. The squares
and associated error bars represent the nonparametric estimates  1 stan-
dard error.
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for selected combinations of associated factors representing plausible pa-
tient profiles. All analyses were performed using SAS version 9.2 (SAS In-
stitute Inc, Cary, NC) and SAS macros from the Cleveland Clinic.5
RESULTS
The analytic cohort included 549 subjects (MBTS 268,
RVPAS 281). The mean follow-up in subjects who survived
and did not undergo cardiac transplant was 2.7  0.9 years,
with a maximum follow-up of 4.4 years. There were 178
deaths: 100 in the MBTS group and 78 in the RVPAS group.
More than one third (39%) were of cardiovascular cause,TABLE 1. Multivariable model for mortality (total n ¼ 549,178 deaths)
Hazard ratio
Early phase
OPVR vs no OPVR 4.75
No HLHS vs HLHS with AS/MS 4.00
No HLHS vs HLHS with AA/MS 1.75
No HLHS vs HLHS with AS/MA 1.28
No HLHS vs HLHS with AA/MA 2.07
Lower SES score (per 5-point decrease) 1.28
Smaller ascending aorta diameter, per mm 1.23
RVPAS vs MBTS
Term, aortic valve not patent 0.36
Term, aortic valve patent 0.57
Preterm, aortic valve not patent 1.25
Preterm, aortic valve patent 2.97
Constant phase
Lower gestational age, per wk 1.56
Genetic syndrome present vs none 9.34
Genetic syndrome unknown vs none 4.74
RVPAS vs MBTS* 1.10
AA, Aortic atresia; AS, aortic stenosis; HLHS, hypoplastic left heart syndrome;MA,mitral a
artery shunt; MS, mitral stenosis; OPVR, obstructed pulmonary venous return; SES, socio
154 The Journal of Thoracic and Cardiovascular Surg25% had unknown cause, 10%were due to multisystem or-
gan failure, 7% were due to infection, 7% were of pulmo-
nary cause, 5%were due to surgical complications, and 7%
were due to other causes. There were 19 transplants: 7 in the
MBTS group (all occurring within 1 year of randomization)
and 12 in the RVPAS group (half occurring within 1 year of
randomization). A genetic syndrome, diagnosed at a median
age of 0.5 (interquartile range, 0.1–9.0) months, was present
in 26 subjects (5%), including 8 with CHARGE associa-
tion; 5 with Turner syndrome; 4 with Kabuki syndrome; 1
each with DiGeorge, Alagille, Goldenhar, Down, or
Thode-Leonard syndrome; and 4 others with unspecified
syndromes.
Figure 1 displays competing risk time-related prevalence
for the 3 states (death, transplant, survival without trans-
plant). For the entire cohort, the 1- and 3-year mortality
rates were 29% and 33%. The transplant prevalence at 1
and 3 years was 2.5% and 3.6%, respectively. The paramet-
ric curves provide an accurate estimate of the event rates de-
rived from nonparametric modeling (shown by the point
estimates). This concordance indicates that the parametric
regression model provides a suitable fit to the data and is ap-
propriate for identifying factors associated with each state.
The multivariable model for death included several inde-
pendent factors and 2 interactions with shunt type (Table 1).
The hazard for death was characterized by an early phase
and a constant phase that when combined describe the pat-
tern of mortality over time. Clinical factors associated with
the constant phase contribute to the likelihood of death
equally across the entire time period of analysis. Although
early and constant phase factors contribute in varying de-
grees to the hazard of death across the entire time spectrum,95% CI P value Reliability
(2.65–8.52) <.001 88%
(1.91–8.37) <.001
(0.98–3.13) .06
(0.46–1.56) .63
(1.12–3.82) .021
(1.06–1.56) .012 64%
(1.04–1.45) .013 63%
56%, 55%
(0.22–0.60) <.001
(0.49–1.47) .52
(0.66–2.38) .49
(1.43–6.19) .004
(1.28–1.90) <.001 50%
(3.07–28.40) <.001 55%
(2.10–10.72) <.001 78%
(0.43–2.83) .85 78%
tresia;MBTS,modified Blalock–Taussig shunt; RVPAS, right ventricle-to-pulmonary
economic score. *Shunt type forced into model.
ery c July 2012
TABLE 2. Additional pairwise anatomic diagnosis comparisons from
multivariable model for death in Table 1
Comparison Hazard ratio 95% CI P value
AS/MS vs
AA/MA 0.52 (0.23–1.15) .11
AA/MS 0.44 (0.20–0.95) .04
AS/MA 0.32 (0.10–1.00) .05
AA/MA vs
AA/MS 0.84 (0.54–1.31) .46
AS/MA 0.62 (0.23–1.67) .35
AA/MS vs AS/MA 0.73 (0.27–1.98) .54
AA, Aortic atresia; AS, aortic stenosis; MA, mitral atresia; MS, mitral stenosis.
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nantly in the first year after the Norwood procedure. After
this time, the hazard of death up to 4.4 years was predomi-
nantly attributable to constant phase factors. Early phase
factors associated with death included lower SES score
(hazard ratio [HR]¼ 1.28 per 5-point decrease, a decrement
approximately comparing subjects from 2 adjacent SES
quartiles, P ¼ .012), a smaller ascending aorta diameter
(HR ¼ 1.23 per 1 mm decrease, P ¼ .014), the presence
of OPVR, and certain subtypes of cardiac anatomy
(Tables 1 and 2). Subjects with HLHS-aortic stenosis
(AS)/mitral atresia (MA), HLHS-AA/mitral stenosis
(MS), and a diagnosis other than HLHS were at highest
risk of death and had similar mortality. Among subjects
with HLHS and AA, there was no difference in mortality
among those with MA compared with those with MS
(HR ¼ 0.85, P ¼ .46). Mortality was lowest in subjects
with HLHS-AS/MS (Table 1). Two factors were associated
with a constant hazard of death (bothP<.001): the presence
of a genetic syndrome (12/26 subjects with a genetic syn-
drome died) and lower gestational age (HR ¼ 1.56 per de-
creasing week).
In the multivariable model for death, there were 2 signif-
icant 2-way interactions. Shunt type had a significant inter-
action with preterm status (P ¼ .029) and aortic valve
patency (P ¼ .018). Four subgroups resulted from these 2
factors: term infants with an atretic aortic valve (51% of
subjects), term infants with a patent aortic valve (38% of
subjects), preterm infants with an atretic aortic valve (7%
of subjects), and preterm infants with a patent aortic valve
(4% of subjects). We found no significant benefit of either
shunt type for term infants with a patent aortic valve
(P ¼ .57) or for preterm infants with an atretic aortic valve
(P ¼ .49); this represents approximately half the cohort
(45%). The RVPAS was associated with lower mortality
for term infants with an atretic aortic valve (RVPAS vs
MBTS HR ¼ 0.36, P< .001), which represent the other
half of the cohort. The MBTS was associated with lower
mortality for the small subgroup of preterm infants with
a patent aortic valve (RVPAS vs MBTS HR ¼ 2.97,
P ¼ .004).The Journal of Thoracic and CaWe used the parametric regression model to generate pre-
dicted cumulative incidence of death by cardiac anatomy
and shunt type for low-risk subjects (Figure 2, A and B).
The predicted mortality for any patient profile can be ob-
tained from the model. Figure 2, C and D, shows selected
scenarios of poor outcome in those with HLHS and AA/
MS: Subjects with OPVR who are preterm and have
a smaller than average ascending aortic diameter have
less than a 20% chance of survival to 1 year, regardless
of shunt type. Because OPVR is a risk factor associated
with the early phase of the hazard for death, mortality oc-
curs rapidly (by 6–8 months, usually before the stage II pro-
cedure). Subjects with no OPVR, but who have a genetic
syndrome, are preterm, and have a small aortic diameter,
also have less than a 20% chance of survival at 4 years,
but the mortality occurs over time, because genetic syn-
drome is a risk factor associated with the underlying con-
stant (rather than early) hazard of death. Conversely,
Figure 2, E and F, shows selected scenarios of good out-
come. These profiles are for subjects with HLHS with
AS/MS (Figure 2, E) or AA/MA (Figure 2, F) with other
characteristics fixed at SES at the third quartile, no
OPVR, term status, and an above-average ascending aorta
diameter. For these subjects, all have survival more than
70% at 4 years, regardless of shunt type.
Eight variables were associated with an increased risk of
transplant at the P less than .10 level (Table E2). We found
no significant interactions of shunt type and other variables.
The multivariable model for transplant (Table 3) had 3 inde-
pendent factors: lower right ventricle fractional area change
from the pre-Norwood echocardiogram, a diagnosis other
than HLHS, and a larger number of pre-Norwood surgeries
(Table E2 shows the procedure listing). Shunt type was not
associated with transplant (RVPAS vs MBTS HR ¼ 1.46,
95% CI, 0.57–3.70, P¼ .43). The presence of moderate/se-
vere tricuspid regurgitation was also clinically significant
(HR ¼ 2.61), but was not statistically significant
(P ¼ .07) because of its correlation with cardiac anatomy
and number of prior surgeries. Figure 3 shows the cumula-
tive incidence of transplant for 8 patient profiles. For
example, 11% of infants with 35% fractional area change
on pre-Norwood echocardiogram and no pre-Norwood sur-
gery are predicted to undergo transplant by 3 years regard-
less of anatomy, whereas 27% to 36% of infants with
HLHS, 25% fractional area change, and 1 pre-Norwood
surgery will undergo transplantation by that time. One
high-risk scenario is an infant with a diagnosis other than
HLHS, 25% fractional area change, and 1 pre-Norwood
surgery (62%–76% 3-year probability of transplant).
DISCUSSION
The goal of this analysis of the PHN SVR trial dataset
was to identify patient and preoperative factors associated
with the intermediate-term occurrence of death and cardiacrdiovascular Surgery c Volume 144, Number 1 155
FIGURE 2. A, Parametric survival curve by anatomic subtype of subjects undergoing RVPAS. B, Parametric survival curve by anatomic subtype of sub-
jects undergoing MBTS. C, Parametric survival curve for higher-risk subjects, showing the impact of OPVR on survival among subjects undergoing the
Norwood procedure with MBTS versus RVPAS. D, Parametric survival curve for higher-risk subjects showing the impact of a genetic syndrome on survival
among subjects undergoing the Norwood procedure with MBTS versus RVPAS. E, Parametric survival curve for lower-risk subjects, showing the impact of
shunt type, SES, and aortic diameter on survival of subjects with HLHS-AA/MA. F, Parametric survival curve for lower-risk subjects, showing the impact of
shunt type, SES, and aortic diameter on survival of subjects with HLHS-AS/MS. RVPA, Right ventricle-to-pulmonary artery; SES, socioeconomic status;
GA, gestational age; OPVR, obstructed pulmonary venous return; Ao, aorta; diam, diameter; MS, mitral stenosis; MBT, modified Blalock–Taussig; HLHS,
hypoplastic left heart syndrome; AA, aortic atresia; MA, mitral atresia.
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undergoing staged palliation. The candidate factors chosen
for this analysis include those with little or no potential for
modification before surgery. Because these characteristicsTABLE 3. Multivariable model for cardiac transplantation
Variable
Hazard
ratio 95% CI
P
value Reliability
RVPAS vs MBTS* 1.46 (0.57–3.70) .43 —
Lower pre-Norwood RV
fractional area change,%
1.49y (1.12–1.97) .006 60%
HLHS vs other diagnosis 0.32 (0.11–0.89) .029 51%
No. of pre-Norwood surgeries 5.64 (1.69–18.77) .005 54%
HLHS,Hypoplastic left heart syndrome;MBTS,Modified Blalock–Taussig shunt; RV,
right ventricle; RVPAS, right ventricle-to-pulmonary artery shunt. *Shunt type was
forced into the model. yPer 5-unit decrease.
156 The Journal of Thoracic and Cardiovascular Surgare unique to each patient at the time of diagnosis, they
are the factors the teams caring for these neonates must
use to formulate decisions before surgical intervention. Pri-
marily nonmodifiable factors were chosen with the addi-
tional goal of identifying those patient-specific factors
that might allow better assignment to an MBTS or RVPAS
for the Norwood procedure.
By using parametric regression, we characterized the
hazard of death as having a constant phase and an early
phase. Many of these risk factors, specifically OPVR, shunt
type, smaller ascending aorta, non-HLHS anatomy, genetic
syndromes, and lower gestational age, have been identified
in previous retrospective and prospective studies.1,8-12
Although a genetic syndrome was present in only 5% of
the cohort, it had a strong negative association withery c July 2012
FIGURE 3. Predicted probability of freedom from transplant for subjects
with differing cardiac anatomy, right ventricle function, and numbers of
pre-Norwood surgeries. HLHS, Hypoplastic left heart syndrome; RV, right
ventricle;MBTS,modified Blalock–Taussig shunt; RVPAS, right ventricle-
to-pulmonary artery shunt; Nwd, Norwood.
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syndrome were alive at last follow-up. In a recent analysis
of the Society of Thoracic Surgeons and Congenital Heart
Surgeons’ Society databases, the risk of death after the Nor-
wood procedure among patients with chromosomal defects,
the majority of which were Turner syndrome, was increased
and found to be greatest within the first year of the Norwood
procedure.13 Likewise, we found that 10 of the 12 deaths oc-
curring in subjects with a genetic syndrome occurred in the
first year. The specific mechanism of increased risk of mor-
tality is unknown but is likely due to abnormalities of organ
system function specific to each genetic syndrome.12,13 The
poor survival of this group is important to consider during
prenatal and preoperative counseling.
The presence of OPVR also had a high impact on mortal-
ity. This condition is associated with profound hypoxia and
the need for an emergency Norwood procedure or
a pre-Norwood intervention. Although creation of an unre-
strictive atrial septal communication can usually be accom-
plished at the time of surgery, these patients frequently have
persistent abnormalities of the pulmonary vasculature. The
wall of the pulmonary veins can be thickened by the pres-
ence of multiple elastic lamina, normally not seen in pulmo-
nary veins.14,15 Despite anatomic decompression of the left
atrium, these patients have ongoing hypoxia with
a pulmonary vascular bed unsuitable for subsequent single
ventricle palliation. Although we have confirmed the
profound risk associated with OPVR, effective treatment
remains elusive. Attempts at prenatal intervention are
promising but as yet have not resulted in significantly
improved outcomes.15
There were important differences in survival with respect
to anatomic subtype. Consistent with single-center reports,
subjects with a non-HLHS diagnosis, such as unbalanced
atrioventricular canal defect, double-outlet right ventricleThe Journal of Thoracic and Cawith MA, or heterotaxy syndrome, had poorer survival.10
The superior survival among subjects with AS/MS was ob-
served even after adjustment for ascending aortic diameter
but may be due in part to the presence of antegrade flow
withmore reliable coronary circulation and possibly a larger
aortic root and arch, simplifying the Norwood procedure.
Furthermore, the presence of even a small left ventricle
that can contribute to cardiac output may be helpful. Two
large single-center retrospective studies have suggested
that patients with AA/MSmay be at higher risk for death af-
ter stage 1 palliation, possibly because of the higher preva-
lence of coronary artery fistulas.16,17 In this analysis, there
was no significant difference in mortality between
subjects with AA and MA and those with AA and MS.
Our data do not provide justification for alternative
strategies in this group of patients.
We found an important interaction between shunt type
and aortic valve patency, as well as between shunt type
and prematurity, in association with early phase mortality.
Specifically, term infants with an atretic aortic valve had
better survival if they underwent an RVPAS compared
with an MBTS. The benefit of the RVPAS at 12 months,
as previously reported for the SVR trial, seems to be con-
fined, based on a mean follow-up of 2.7  0.9 years, to
this group of 272 subjects (51% of the total cohort).1 The
risk of mortality for a term patient with an atretic aortic
valve undergoing an RVPAS was one third that of a similar
patient undergoing an MBTS. In contrast, among 21 pre-
term infants (4% of the cohort) with a patent aortic valve,
survival was better with an MBTS. For the 45% of the sub-
jects outside of these 2 groups (ie, term patients with a patent
aortic valve and preterm patients with AA), we were unable
to demonstrate a significant association between shunt type
and mortality. Among the postulated benefits of the RVPAS
is improved coronary artery perfusion.18-20 The RVPAS
results in a higher diastolic pressure, and thus a higher
coronary artery driving pressure, which may provide an
important benefit to the patient with AA. In contrast with
patients with a patent aortic valve, patients with AA are
more likely to have coronary artery anomalies including
fistulas.21,22 Furthermore, patients with an atretic aortic
valve are more likely to have a smaller ascending aorta,
making surgical construction of an unobstructed
connection between the ascending aorta and the main
pulmonary artery more technically challenging. Indeed,
obstruction in this connection, which can impair coronary
artery blood flow in the presence of AA, has been cited as
a cause of death among patients undergoing the Norwood
procedure.23 The more favorable hemodynamics of the
RVPAS may ameliorate mild obstruction that could other-
wise result in critical coronary artery insufficiency, myocar-
dial ischemia, and death among similar patients with an
MBTS. Therefore, the benefit of the RVPAS over the
MBTS in term newborns with AA may be explained byrdiovascular Surgery c Volume 144, Number 1 157
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favorable among preterm subjects with a patent aortic valve
is less clear. Perhaps the ventriculotomy in a small heart is
less well tolerated and overwhelms other risk factors. It
must be emphasized that only 11% of the subjects in this
trial were preterm.
This analysis studied factors that are known about the
newborn with HLHS before surgical intervention and that
are the basis for decision-making by the teams caring for
the patient with HLHS. They are generally considered non-
modifiable, but in fact 2 of the factors, gestational age and
SES, might be modifiable. This study and single-center
studies of outcome have identified the importance of gesta-
tional age as a risk factor for mortality, as well as for neuro-
developmental outcome.9-12 Although some early deliveries
are inevitable, the increased risk of mortality should be
taken into consideration if earlier elective delivery is
considered. In the case of SES, the impact on survival is
thought to be due to limited access to health care
resources.24 Therefore, provision of services to compensate
for the challenges associated with low SES may positively
affect outcome.
Given the high mortality of subjects after the Norwood
procedure, it seems at first surprising that there was such
a low use of transplantation. Although the decision-
making process concerning the use of transplantation in
this group is beyond the scope of this study, it is noteworthy
that many of the factors associated with mortality, such as
OPVR and a genetic syndrome, are often considered contra-
indications for transplant.25 Furthermore, multiorgan dys-
function that occurs as a consequence of inadequate
cardiac output after the Norwood procedure may also pre-
clude the use of transplantation as salvage therapy. The rel-
ative lack of donor availability also limits use of this
therapy. These data suggest that transplantation may be an
alternative for only a small fraction of patients at risk for
mortality after the Norwood procedure.
Study Limitations
This analysis has several limitations. We had limited
power to detect interactions of shunt type and patient sub-
group when subgroup sizes were small and to detect differ-
ences in mortality for selected subgroups regardless of
shunt. For example, the difference in mortality between
patients with HLHS with AA/MA versus those with AS/
MS was 2-fold, clinically significant, but of marginal sta-
tistical significance. There was also low power to identify
statistically significant risk factors for transplantation be-
cause of the small number of such events. Nevertheless,
the risk models developed for both mortality and trans-
plantation included multiple independent factors and
have clinical relevance. Finally, the presence versus ab-
sence of a genetic syndrome was unknown for one third
of subjects, and the increased HR for death relative to158 The Journal of Thoracic and Cardiovascular Surgsubjects without a genetic syndrome reflects in part mor-
tality that occurred before a genetic evaluation could be
performed.
CONCLUSIONS
These data suggest that term patients with AA have
better outcomes with an RVPAS and that preterm infants
with a patent aortic valve may have better outcomes with
an MBTS. For slightly less than half of the cohort, non-
modifiable factors did not aid in shunt selection. Lower
gestational age and SES, as well as the presence of a ge-
netic syndrome, are also independent predictors of mor-
tality. Transplant was used in only 3% of subjects after
the Norwood procedure. Right ventricular function and
anatomy, but not shunt type, were associated with trans-
plantation. Patient-specific factors associated with mortal-
ity after the Norwood procedure are frequently
contraindications to transplantation. Effective alternative
therapies for the highest-risk Norwood candidates remain
elusive.
The authors thank Dr Eugene Blackstone and Jeevanantham
Rajeswaran for guidance on this analysis.
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TABLE E1. Patient characteristics and association with mortality by phase
Variable Mean ± SD or %
Early phase Constant phase
HR P value HR P value
RVPAS vs MBTS 51% vs 49% 0.58 .002 1.64 .32
Prenatal
Prenatal diagnosis 77% .87 .45 1.89 .38
Fetal intervention 2.7% – – – –
Birth
Gestational age, wk 38.2  1.6 .89 .030 0.65 <.001
Gestational age<37 wk 12% 2.31 <.001 3.61 .028
Apgar at 1 min 7.6  1.6 0.94 .21 0.997 .94
Apgar at 5 min 8.6  0.8 .85 .07 0.89 .61
Birth weight, kg 3.10  5.41 0.59 .001 0.69 .42
Birth weight<2.5 kg 14% 2.10 <.001 2.13 .21
Birth weight<1.5 kg 0.4% 2.96 .29 18.4 .006
Demographic
Male 62% 0.81 .22 2.04 .25
Hispanic 19% 1.06 .88 0.58 .68
White race 80% 0.80 .27 0.68 .50
SES score, US census (HR per 5-point decrease) 0.05  5.08 1.27 .006 0.88 .57
Anatomy
HLHS 88% 0.60 .019 1.90 .54
AA, MA 38% 0.93 .69 1.14 .81
AA, MS 25% 1.22 .49 0.44 .40
AS, MS 12% 0.32 .008 2.22 .19
Any AA 62% 1.07 .70 0.53 .25
Obstructed PV drainage 3.5% 4.30 <.001 Not estimable
Total anomalous pulmonary venous return 1.6% 2.09 .33 8.25 .27
Ascending aorta diameter, mm 3.15  1.75 0.87 .018 1.07 .56
Genetic syndrome
Yes vs no 5% 1.48 .45 7.91 .001
Unknown vs no 32% 3.30 <.001 2.78 .049
Non-syndromic abnormality
Yes vs no 19% 0.77 .43 2.02 .22
Unknown vs no 32% 3.00 <.001 2.89 .05
Pre-Norwood echocardiography
Patent aortic valve 42% 0.88 .35 1.66 .28
ASD mean Doppler gradient, mm Hg 5.0  3.0 1.02 .55 0.97 .69
RV fractional area change 0.35  0.09 2.07 .49 0.63 .91
LV present 69% 0.95 .77 1.26 .68
Moderate/severe tricuspid regurgitation 12% 1.24 .42 2.54 .13
Moderate/severe mitral regurgitation 4% 0.41 .29 .008 .58
Moderate/severe aortic valve regurgitation 0.8% 0.10 .54 0 .40
Preoperative
Median highest lactate, mmol/L (IQR) 3.1 (2.5, 4.5) 1.06 .018 0.84 .26
Mechanical ventilation 48% 1.73 .002 0.97 .95
Pre-Norwood apnea 14% 1.34 .18 0.94 .89
Pre-Norwood shock 2.6% – – – –
Pre-Norwood respiratory failure 13% 1.09 .76 3.02 .045
Pre-Norwood metabolic acidosis 5.7% 1.05 .99 0.69 .97
Pre-Norwood catheter intervention 5.1% 2.24 .005 0 .95
No. of pre-Norwood catheter intervention (median [IQR]) 0.07  0.32
(0 [0–0])
2.24 .005 0 .95
Pre-Norwood noncardiac surgery 1.5% 0.53 .69 4.55 .19
Pre-Norwood any surgery 2.0% – – – –
No. of pre-Norwood total surgeries (median [IQR]) 0.02  0.17
(0 [0–0])
1.21 .61 1.42 .75
(Continued)
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TABLE E1. Continued
Variable Mean ± SD or %
Early phase Constant phase
HR P value HR P value
Pre-Norwood complications 28% 1.57 .011 1.14 .80
No. of pre-Norwood complications (median [IQR]) 0.58  1.23
(0 [0–1])
1.16 .003 0.91 .71
SD, Standard deviation; HR, hazard ratio; RVPAS, right ventricle-to-pulmonary artery shunt; MBTS, modified Blalock–Taussig shunt; SES, socioeconomic status; HLHS,
hypoplastic left heart syndrome; ASD, atrial septal defect; IQR, interquartile range; LV, left ventricle.
TABLE E2. Results summary for cardiac transplant risk factors with univariate P value less than .2 and for shunt type
Transplant No transplant
Variable Mean ± SD or% (n) Hazard ratio 95% CI P value
N 19 530
RVPAS vs MBTS 63% (12) 51% (269) 1.43 (0.56–3.63) .45
Male vs female 42% (8) 63% (332) 0.42 (0.17–1.04) .06
Percentage in census tract below
federal poverty level
7.6  7.2 13.1  12.4 1.31 per 5% increase (0.96–1.80) .09
HLHS 74% (14) 88% (467) 0.33 (0.19–0.55) .03
HLHS with AS/MS 5% (1) 21% (109) 0.18 (0.02–1.36) .10
HLHS with AS/MA 11% (2) 3% (15) 4.05 (0.94–17.5) .06
Total anomalous pulmonary venous
connection
5% (1) 2% (8) 6.03 (0.80–45.6) .08
Pre-Norwood moderate/severe
tricuspid regurgitation
32% (6) 11% (59) 3.86 (2.29–6.18) .006
Pre-Norwood RV fractional area change 0.30  0.09 0.35  0.08 1.43 per 5-unit decrease (1.09–1.85) .009
Total No. of pre-Norwood surgeries* 0.11  0.46 0.02  0.15 4.21 (1.30–13.7) .017
AS, Aortic stenosis; CI, confidence interval; HLHS, hypoplastic left heart syndrome; MA, mitral atresia; MBTS, modified Blalock–Taussig shunt; MS, mitral stenosis; RV, right
ventricular; RVPAS, right ventricle-to-pulmonary artery shunt; SD, standard deviation. *Includes 1 subject with atrial septectomy and bilateral pulmonary artery bands, 2 subjects
with bowel surgery, 1 subject with extracorporeal membrane oxygenation, 1 subject with exploratory laparotomy, 1 subject with choanal atresia and stent placement, and 1 subject
with tracheoesophageal fistula repair
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